|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0100 AUD | -.--% |
|
-16.67% | -33.33% |
| 05-28 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 05-27 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 6.16M 4.32M 3.76M 3.5M 3.21M 6.07M 413M 41.23M 16.18M 205M 16.24M 15.88M 689M | P/E 2024 |
-3.44x | P/E 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 8.93M 6.27M 5.45M 5.07M 4.66M 8.79M 598M 59.79M 23.47M 298M 23.54M 23.03M 999M | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/05/22 | Acrux : Application for quotation of securities - ACR | PU |
| 14/04/22 | Acrux : Application for quotation of securities - ACR | PU |
| 16/03/22 | Acrux : Application for quotation of securities - ACR | PU |
| 25/02/22 | Acrux : Updated Board Charter | PU |
| 25/02/22 | Acrux : Application for quotation of securities - ACR | PU |
| 1 week | -16.67% | ||
| 1 month | -23.08% | ||
| 3 months | -16.67% | ||
| 6 months | -33.33% | ||
| Current year | -33.33% |
| 1 week | 0.01 | 0.01 | |
| 1 month | 0.01 | 0.01 | |
| Current year | 0.01 | 0.02 | |
| 1 year | 0.01 | 0.02 | |
| 3 years | 0.01 | 0.1 | |
| 5 years | 0.01 | 0.14 | |
| 10 years | 0.01 | 0.78 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 01/06/2025 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21/06/2021 |
| Chief Tech/Sci/R&D Officer | - | 15/02/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ross Dobinson
CHM | Chairman | 74 | 01/01/2006 |
Timothy Oldham
BRD | Director/Board Member | - | 01/10/2013 |
Geoff Brooke
BRD | Director/Board Member | 70 | 01/06/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -16.67% | -41.18% | -79.59% | 3.6M | ||
| -0.53% | +2.54% | +22.14% | +74.08% | 50.03B | ||
| -1.81% | -0.49% | +48.83% | +107.71% | 36.6B | ||
| +0.46% | +4.44% | -1.97% | +25.02% | 12.47B | ||
| +1.05% | +1.63% | +18.73% | +77.76% | 11.77B | ||
| -1.33% | -0.76% | +30.73% | +127.63% | 9.04B | ||
| -2.99% | -2.09% | +45.28% | -11.87% | 7.03B | ||
| +0.51% | +1.46% | +13.46% | +32.06% | 6.79B | ||
| +1.99% | +1.91% | +8.03% | +183.42% | 6.6B | ||
| +0.39% | +3.39% | -35.25% | +4.49% | 5.49B | ||
| Average | -0.23% | -0.80% | +10.88% | +54.07% | 14.58B | |
| Weighted average by Cap. | -0.61% | +1.27% | +24.94% | +78.17% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.09M 3.57M 3.11M 2.89M 2.65M 5.01M 341M 34.08M 13.38M 170M 13.42M 13.13M 569M | 1.19M 835K 726K 676K 621K 1.17M 79.74M 7.97M 3.13M 39.7M 3.14M 3.07M 133M |
| Net income | -5.8M -4.07M -3.54M -3.29M -3.02M -5.71M -389M -38.83M -15.24M -193M -15.29M -14.95M -649M | -5.94M -4.17M -3.63M -3.38M -3.1M -5.85M -398M -39.8M -15.62M -198M -15.67M -15.33M -665M |
| Net Debt | 759K 533K 463K 431K 396K 747K 50.86M 5.08M 1.99M 25.32M 2M 1.96M 84.9M | 2.77M 1.95M 1.69M 1.57M 1.45M 2.73M 186M 18.56M 7.28M 92.47M 7.31M 7.15M 310M |
Employees
43
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/07/26 | A$0.0100 | -.--% | 62,766 |
| 30/07/26 | A$0.0100 | -9.09% | 3,698,957 |
| 29/07/26 | A$0.0110 | -.--% | 1,429,995 |
| 28/07/26 | A$0.0110 | -.--% | 2,638,948 |
| 27/07/26 | A$0.0110 | -8.33% | 169,956 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
Select your edition
All financial news and data tailored to specific country editions
















